



Patent Application
Attorney Docket No. PC 9137B

A/FWC
#11/D
2/9/98
C. style

EXPRESS MAIL CERTIFICATION

Express Mail Label No. EM57101181US, Date of Deposit: October 20, 1997 I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to: Washington, D.C. 20231.

By

(Signature of person transmitting and mailing)

Lorraine B. Ling

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Hon. Commissioner of Patents and Trademarks
Box FWC
Washington, D.C. 20231

TRANSMITTAL OF REQUEST FOR FILING UTILITY
PATENT APPLICATION PURSUANT TO 37 C.F.R. § 1.62

Sir:

This is a request for filing a ☒ continuation ☐ divisional application under 37 CFR 1.62, of pending prior application serial no. 08/470,786 filed on (date) June 6, 1995 of BATESON, JOHN H.; BURTON, GEORGE; and FELL, STEPHEN C.M.; for CEPHALOSPORINS AND HOMOLOGUES, PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS which is hereby expressly abandoned in view of 37 CFR 1.62(g).

1. ☒ The application filing fee is calculated below:

BASIC APPLICATION FEE: \$790.00
CLAIMS FEES:

CLAIMS AS FILED IN THE PRIOR APPLICATION, LESS ANY
CLAIMS CANCELLED BY AMENDMENT BELOW

Total Claims	<u>11</u>	-20=	<u>0</u>	x \$22.00	<u>0.00</u>
Independent Claims	<u>3</u>	- 3=	<u>0</u>	x \$82.00	<u>0.00</u>
<input type="checkbox"/> Multiple Dependent Claim(s) fee				\$270.00	<u>0.00</u>
Total Filing Fee					<u> </u>

2. ☒ Please charge Deposit Account No. 16-1445 in the amount of \$790.00. Two copies of this paper are enclosed.

- ☒ The Commissioner is hereby authorized to charge any fees which may be required under 37 C.F.R. §§ 1.16 and 1.17, or credit any overpayment to Account No. 16-1445. Two copies of this paper are enclosed.

D



- ☒ Cancel in this application original claims 1 to 56, of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes).

4. ☒ Amend the specification by inserting before the first line the sentence:

-- This is a ☒ continuation, ☐ division, of application serial no. 08/470,786, filed on June 6, 1995, ^{ABN} which is a continuation of application serial no. 07/934,667, filed January 22, 1993. ^{ABN}

5. ☒ Priority of application serial no. 9016189.4 filed on July 24, 1990 in Great Britain and 9109540.6 filed May 2, 1991 in Great Britain is claimed under 35 U.S.C. § 119.
- ☒ The certified copy has been filed in prior application serial no. 07/934,667, filed January 22, 1993.
6. ☒ The prior application is assigned of record to Pfizer Inc..
7. ☒ The power of attorney in the prior application is to (name, registration number, and address):

DECLARATION

**ATTORNEY and/or AGENT INFORMATION
(Supplemental Sheet)**

Name	Registration Number	Name	Registration Number
PETER C. RICHARDSON	27,526	ALLEN J. SPIEGEL	25,749
AARON PASSMAN	26,783	LAWRENCE C. AKERS	28,587
J. TREVOR LUMB	28,567	MARK DRYER	28,775
RAYMOND W. AUGUSTIN	28,588	JOHN L. LAPIERRE	29,185
PAUL H. GINSBURG	28,718	GREGG C. BENSON	30,997
ELIZABETH O. SLADE	29,011	ROBERT F. SHEYKA	31,304
JAMES T. JONES	30,561	GROVER F. FULLER, JR.	31,760
A. DEAN OLSON	31,185	KAREN DEBENEDICTIS	32,977

HOWARD R. JAEGER	31,376	PHILIP C. STRASSBURGER	34,258
MERVIN E. BROKKE	32,723	LORRAINE B. LING	35,251
VALERIE M. FEDOWICH	33,688	GARTH BUTTERFIELD	36,997
BRYAN C. ZIELINSKI	34,462	B. TIMOTHY CREAGAN	39,156
ROBERT T. RONAU	36,257	ALAN L. KOLLER	37,371
CARL J. GODDARD	39,203		
RAYMOND M. SPEER	26,810		
GEZINA HOLTRUST	28,222		

- a. ☐ The power appears in the original papers in the prior application.
- b. ☐ Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- c. ☒ Address all future communications to Dr. Peter C. Richardson, Pfizer Inc., 235 East 42nd Street, New York, New York 10017-5755. (May only be completed by applicant, or attorney or agent of record).
8. ☐ A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application).

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of

Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: October 20, 1997

Lorraine B. Ling
Lorraine B. Ling

Pfizer, Inc.
Patent Dept.
235 East 42nd Street
New York, N.Y. 10017-5755
(212) 573-2030

- ☐ Inventor(s)
☐ Assignee of complete interest
☒ Attorney or agent of record, _____
Reg. No. 35,251
☐ Filed under § 1.34(a)

(Note: Mark "Box FWC" on envelope.)